Participated · Series B · Aug 2026

Inocras develops whole-genome sequencing and proprietary bioinformatics solutions to translate comprehensive genomic data into curated, clinically actionable insights. Its oncology offerings include CancerVision™ for comprehensive tumor profiling and MRDVision™ for molecular residual disease detection, with automated interpretation capabilities. The company operates a CLIA/CAP-certified laboratory and reports real-world clinical adoption across Asia, with its solutions used by more than 100 cancer institutions and in thousands of patient cases. Inocras has established a significant commercial presence in Hong Kong and supports approximately thirty hospitals in South Korea. The company has collaborated with researchers at the Broad Institute to analyze whole-genome data from The Cancer Genome Atlas, informing broader use of standardized whole-genome analysis. The recent fundraise brought total funding to approximately $100 million to support further commercial expansion, particularly into the United States.

Participated · Series A · Jul 2026

MID develops and manufactures space-grade electronic components and operates a consulting business for space product assurance, leveraging its Component Procurement & Provision Activity (CPPA) platform. The company localized a hermetically sealed ceramic-package 16Mbit SRAM designated as a ‘Space New Technology’ and installed on a technology validation satellite launched on the Nuri rocket. It is developing a non-hermetic epoxy-molding high-capacity NAND flash (128Gbit or more) intended for the ultra-small satellite DaejeonSat to be launched on the fifth Nuri mission. MID plans to build a 6,600-square-meter advanced packaging line in Daejeon and to scale mass-production processes for HTCC ceramic packages. The company reported revenue rising from about KRW 1.9 billion in 2021 to roughly KRW 12.4 billion last year and aims to expand into commercial and defense markets while establishing production for ceramic components used in semiconductor test equipment by 2029.

Led · Series A · Jul 2026

CarbonSix develops deployment-ready robotic intelligence software and hardware, including robotic hands and manipulators, for manufacturing applications. The company emphasizes field reliability and immediate integration into production lines, and reports commercial contracts and scaling revenue as evidence of market traction. Its core business model is a proprietary "data flywheel" where tool usage in factories generates task-specific data that improves its AI models over time. The founding team includes executives and researchers with prior exits and advanced academic credentials, supporting technical and commercial credibility. CarbonSix plans to use its Series A proceeds to hire talent, scale infrastructure, and expand into global markets.

Led · Series A · Apr 2026

V1C develops financial technology solutions leveraging AI, data analytics, and cloud infrastructure to deliver personalized financial recommendations and secure transaction processing. Its core SaaS product, Clobe AI, aggregates financial data from bank accounts, credit cards, and tax invoices to provide real-time cash flow insights and profit-and-loss analysis. According to the article, Clobe AI serves over 10,000 corporate customers. Following the pre-Series A, the company plans to expand the platform, enhance its financing capabilities, and scale partnerships and product development. The company is headquartered in Seoul and operates in the fintech / AI financial management SaaS space.

Led · Series B · Feb 2026

BreezeBio, formerly GenEdit, engineers polymer-based NanoGalaxy nanoparticles that deliver genetic payloads such as mRNA with cell-type precision across immune, cardiac, pulmonary and central nervous system tissues. The company has shifted from being solely a delivery-technology provider to building a therapeutic pipeline concentrated on autoimmune disease and oncology. Its lead candidate, BRZ-101, delivers autoantigen-encoding mRNA and tolerogenic co-factors to antigen-presenting cells to induce antigen-specific regulatory T cells and aims to restore immune tolerance in type 1 diabetes; the program is now entering IND-enabling studies after positive preclinical results in mice and non-human primates. BreezeBio is also extending NanoGalaxy with ligand conjugation to reach T cells and enable in vivo CAR-T therapies. Beyond internal programs, the firm maintains a multi-year collaboration and licensing agreement with Genentech that has already produced an initial milestone payment. The recent financing strengthens its balance sheet, allowing continued platform expansion and clinical advancement of its pipeline.